Buy Evolent Health

Logo for stock EVH (Evolent Health)

Amount

£
GBP

Latest price

$9.98
(£1.00 = $1.328)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$1.172B

P/E ratio

-8.18

EPS

-$1.22

Beta

0.73

Dividend rate

N/A

Dividend yield

N/A

About

Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers three primary solutions: specialty care management services, total cost of care management and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or accountable care organizations (ACO) contracts with Centers for Medicare and Medicaid Services (CMS). Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.

CEO

Mr. Seth Blackley

Employees

4,500

Sector

Services

Company HQ

ARLINGTON, United States of America

News

Logo for news article #0 (Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline)

Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research

July 31, 2025

Logo for news article #1 (Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025)

Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Company to Participate in Upcoming Conferences WASHINGTON , July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

PRNewsWire

July 14, 2025

Logo for news article #2 (Evolent announces key appointments to leadership team)

Evolent announces key appointments to leadership team

Dr. David Lim joins Evolent as chief clinical officer John Way joins Evolent as CFO, Performance Suite WASHINGTON , July 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced leadership additions to its clinical and financial teams, as it continues to drive innovation in specialty care. Physician, executive and startup entrepreneur Dr. David Lim has joined the company as chief clinical officer, where he will lead Evolent's 300-person medical team to support daily operations and innovation.

PRNewsWire

July 09, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.